Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.
Original Article: Durvalumab/Tremelimumab Misses Endpoint in Phase III NSCLC Study